Mouse
studies suggest a polyethylene glycol formulation of docetaxel
conjugated to acetylated carboxymethylcellulose could help treat breast cancer.
The conjugated docetaxel self-assembled into 120 nm-diameter nanoparticles,
called Cellax.
In an orthotopic mouse model of breast cancer, injection of Cellax decreased
both the number of a-SMA-expressing
stromal cells within the tumor and metastasis compared with injection of Abraxane nab-paclitaxel or
native docetaxel. Next steps include manufacturing Cellax in preparation for
Phase I trials. Celgene Corp. and Otsuka Pharmaceutical Co. Ltd.
market Abraxane to treat breast cancer (see Going
stromal with docetaxel, page 6).

Access this BioCentury Innovations article Distillery article for your individual use via a permanent link that allows you to read or print the article: $18.
The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.

Purchase This Article for Limited One-Time Distribution and Posting to Your Website :

Receive a formatted PDF reprint of this article with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.

Purchase Options

Purchase this article for individual use $18 USDPurchase this article for limited one-time distribution and website posting $750 USD